Key Terms & Concepts — UPSC Mains
Biologics and Biosimilars Regulation
"The regulatory framework governing the approval, manufacturing, and market entry of complex biologic medicines and their near-identical copies (biosimilars)"
Biologics are large, complex molecules derived from living organisms (cells, tissues, recombinant DNA, or proteins) used to treat diseases like cancer, rheumatoid arthritis, and diabetes. Unlike small-molecule drugs that can be exactly replicated as generics, biologics cannot be identically copied due to their structural complexity — their near-replicas are called biosimilars. Biosimilars regulation establishes the scientific, clinical, and manufacturing standards required to prove that a biosimilar is highly similar to the reference biologic with no clinically meaningful differences in safety, purity, or potency.
India is the world's largest producer of biosimilars, with companies like Biocon, Dr Reddy's, and Zydus Lifesciences exporting to the US and EU. The biosimilars market is projected to reach $100 billion globally by 2030 as patents on blockbuster biologics expire. UPSC tests this under GS3 (Science and Technology — biotechnology, pharma) and GS2 (health policy, regulation). India's regulatory capacity for biosimilars is a key component of its pharma superpower narrative.
- 1 The Central Drugs Standard Control Organisation (CDSCO) under the Drugs Controller General of India (DCGI) regulates biologics and biosimilars in India
- 2 India issued Guidelines on Similar Biologics in 2012 (updated 2016) — among the first comprehensive biosimilar regulatory frameworks globally
- 3 Biologics are regulated under the Drugs and Cosmetics Act, 1940 and New Drugs and Clinical Trials Rules, 2019
- 4 Key difference from generics — a generic drug is chemically identical to the reference drug; a biosimilar is highly similar but not identical due to the inherent variability of biological manufacturing
- 5 India's biosimilar exports exceeded $4 billion in 2024; Biocon Biologics is the world's largest pure-play biosimilars company
- 6 Biosimilars offer 20-40% cost savings over reference biologics, improving access to expensive cancer and autoimmune disease treatments
- 7 The US FDA's Biologics Price Competition and Innovation Act (BPCIA, 2009) and the EU's biosimilar pathway (2004) are the global benchmark regulatory frameworks
- 8 Interchangeability — whether a pharmacist can substitute a biosimilar for the reference biologic without physician approval — remains a regulatory and clinical debate
Biocon's biosimilar of trastuzumab (Herceptin, used in breast cancer) was approved by the US FDA and launched at approximately 15% lower cost than the reference product, making life-saving cancer treatment accessible to thousands of patients who could not afford the originator biologic.